Alcon Pays $550 Million for Neurotech and Its Approved Eye Cell Therapy

Alcon said on Monday, Oct. 20, 2026, that it has acquired privately held Neurotech Pharmaceuticals for $550 million upfront plus undisclosed milestone payments, buying the only FDA-approved treatment for a rare cause of central vision loss and a cell-therapy platform the eye care company has never had.

The deal

Alcon, the Geneva-based eye care company listed in Zurich and New York, announced the transaction as already completed. The $550 million is paid upfront, and Alcon may owe additional contingent payments tied to commercial milestones; it did not disclose their size or timing, according to BioPharm International and Fierce Pharma. Goldman Sachs advised Alcon, and J.P. Morgan Securities was lead financial adviser to Neurotech, according to the announcement as carried by Investing.com. Cravath, Swaine & Moore represented Neurotech on the legal side.

Alcon told investors the purchase will be modestly accretive to net sales growth and slightly dilutive to core diluted earnings per share in 2027, then accretive after that. None of the deal coverage described a pending antitrust review, and the companies did not say when Alcon will seek approvals outside the United States.

“Neurotech’s innovative platform sits at the intersection of cell therapy, pharmaceuticals, and surgery,” Alcon Chief Executive David Endicott said in the announcement, as quoted by Fierce Pharma. Analysts at Needham said the acquisition “could become a significant revenue growth driver over time,” MT Newswires reported via MarketScreener.

What Alcon is buying

The asset at the center of the deal is Encelto, known generically as revakinagene taroretcel-lwey. The Food and Drug Administration approved it in March 2025 under priority review, with orphan drug designation, for adults with idiopathic macular telangiectasia type 2, a rare, progressive retinal disease commonly called MacTel that causes irreversible loss of central vision.

Encelto is not a pill or a routine injection. It is a small semipermeable capsule, surgically implanted in the eye, that holds engineered cells producing recombinant human ciliary neurotrophic factor, a protein that protects photoreceptors. The capsule releases it continuously, which is why Alcon and Neurotech present the platform as a possible alternative to repeated injections for chronic retinal disease.

The market is small and defined. Alcon and Neurotech estimate about 25,000 people in the United States have been diagnosed with MacTel, with 2,000 to 3,000 new diagnoses each year. Encelto is currently available only in the United States, and because Neurotech was private, its sales have never been disclosed. That leaves the deal’s revenue multiple unknowable from public information; the calculator below lets readers test their own assumptions.

The evidence and its limits

Encelto’s approval rested on two randomized, sham-controlled phase 3 trials that together enrolled 228 participants and followed them for 24 months, with the rate of photoreceptor loss, measured as ellipsoid zone loss, as the primary endpoint. In a review of the data published with the deal coverage, BioPharm International noted that both trials favored treatment but that the effect was smaller in the second, and that results on reading speed and retinal sensitivity were mixed across the two studies.

The delivery method is also a commercial variable. An implant that requires surgery reaches patients through retina surgeons and operating rooms rather than an office injection visit, which can slow adoption even when demand exists.

How it fits Alcon’s playbook

Alcon has built its pharmaceutical business through mid-sized acquisitions. Fierce Pharma tallied the record: $355 million for Novartis’s glaucoma drug Simbrinza in 2021, $770 million for Aerie Pharmaceuticals in 2022, and $60 million for two Kala Pharmaceuticals eye drops the same year. In 2025, the FDA approved Alcon’s dry eye treatment Tryptyr. The company reported $5.5 billion in revenue for the first half of 2026, up 9 percent.

Neurotech is a different kind of purchase. Instead of a drop or a drug that fits an existing sales call, it brings a living-cell implant that depends on surgical skill, an area where Alcon already sells equipment to retina specialists. That overlap is the strategic logic Endicott pointed to.

The rest of the week in healthcare deals

The Neurotech purchase landed in a busy week for healthcare deals. On Oct. 19, Germany’s Merck KGaA agreed to buy UK biotech Silence Therapeutics for $20 per American depositary share in cash, valuing the company at about $1.3 billion in equity and $1.1 billion in enterprise value. The price is an 82 percent premium to Silence’s 30-day volume-weighted average of $10.99. The deal, structured as a UK scheme of arrangement, needs regulatory and shareholder approvals and is expected to close in the first quarter of 2027. Merck KGaA gets divesiran, a phase 3-ready siRNA therapy for polycythemia vera.

In the public markets, protein-degrader developer Lycia Therapeutics raised about $318 million in an upsized initial public offering and began trading on Nasdaq under the ticker LYCA, according to BioPharma Dive and Renaissance Capital. Renaissance reported a 67 percent first-day gain and a market value of about $1.1 billion. Among hospital systems, New Jersey’s Hackensack Meridian Health and Hunterdon Health signed a definitive merger agreement on Oct. 20 under which Hackensack Meridian commits $200 million in capital investment and $30 million to extend its Epic health record system, subject to state and federal regulatory reviews, NJBIZ reported.

Paxton-Digital’s Take

The week’s two most closely watched drug-asset acquisitions show buyers paying for certainty in different currencies. Merck KGaA paid a steep premium for a single phase 3-ready asset with strong mid-stage data. Alcon paid a smaller sum for something already approved, already on the U.S. market and already in surgeons’ hands, accepting a small patient population and an undisclosed sales base in exchange for no regulatory risk on the lead product.

The Alcon deal also signals that the line between device companies and drug companies keeps blurring. An encapsulated cell implant is a biologic, a device and a surgical procedure at once. Companies that already own the surgeon relationship are well placed to commercialize that kind of product, and that may make other approved but sub-scale cell and gene therapies attractive targets for medtech buyers, not only for pharma.

The open questions are the ones Alcon did not answer: the size of the milestone payments, the timing of approvals outside the United States, and how quickly a surgically implanted therapy can grow. The 2027 earnings guidance suggests Alcon expects a slow ramp.

What it means for you

• Investors should watch Alcon’s next quarterly report for Encelto sales disclosure and any guidance on milestone payments, the two numbers needed to judge the price.
• Private cell and gene therapy companies with an approved product and a narrow market now have another precedent for a strategic exit outside big pharma.
• Retina practices and surgery centers should expect a larger commercial push behind Encelto as Alcon’s sales force takes it over.
• Silence shareholders face a scheme vote and regulatory reviews before the expected first-quarter 2027 close; the premium is fixed in cash.